Participated · Series B · Mar 2020

Harbour BioMed develops next-generation biologics—primarily fully human monoclonal antibodies—targeting cancer, immunologic diseases and COVID-19. The company builds its pipeline using two patented transgenic mouse platforms (Harbour Mice®), including HCAb and H2L2, and integrates technologies such as HBICE™ and the Beacon® Optofluidic System to accelerate discovery. HBM reports more than 30 programs and currently has five products in clinical development, including HBM9161 (anti-FcRn), HBM9036 (Tanfanercept) and HBM4003 (anti-CTLA4). It maintains collaborations with AbbVie, Utrecht University, Erasmus Medical Center and Mount Sinai to advance therapeutic and COVID-19 antibody programs. HBM has operations in Cambridge, Massachusetts; Rotterdam, The Netherlands; and Suzhou and Shanghai, China. The company completed a $102.8M Series C (following a $75M Series B+ in March 2020) to support final development and initial commercialization of late-stage assets and to advance earlier-stage discovery programs. Harbour BioMed (HBM) is a clinical-stage biopharmaceutical company building a proprietary pipeline of next-generation biotherapeutics, including fully human heavy chain only antibodies (HCAb) and bispecifics. Its discovery platforms include patented Harbour Mice® transgenic mouse platforms and the HBICE™ immune cell engager technology, which the company also licenses. HBM is advancing multiple clinical-stage assets, including HBM4003 (anti-CTLA-4), HBM9161 (anti-FcRn), HBM9036 (dry eye disease) and HBM9167 (anti–PD-L1), and has collaborations such as with Mount Sinai Health System on COVID-19. The company has ongoing and planned international clinical studies, has received an IND approval from the FDA for HBM4003, and has reported recent progress toward mid-late stage trials and registration studies. HBM has operations in Cambridge, Massachusetts; Rotterdam, The Netherlands; and Suzhou and Shanghai, China. The company completed an $85 million Series B in August 2018 and has now raised additional capital to accelerate its pipeline. Harbour BioMed centers its discovery and development efforts on two patented transgenic mouse platforms (Harbour Mice) to generate fully human therapeutic antibodies. The company builds a proprietary pipeline through internal discovery and by in‑licensing clinical‑stage assets, and it also licenses its platforms to companies and academic institutions via its Harbour Antibodies subsidiary. Its programs include an anti‑FcRn antibody for multiple autoimmune diseases and a biologic for inflammatory dry‑eye disease (developed for Greater China), a CD3‑based bispecific against HER2 (for Greater China), and a clinical‑stage anti‑PD‑L1 antibody being developed worldwide outside China. Harbour has expanded collaborations around its transgenic technologies and established preclinical and clinical development operations and an experienced team since its founding. Financially, the company has progressed from a December 2016 Series A (around $50M) and an A+ round in early 2018 to a newly completed Series B to support pipeline advancement. The company lists operations in Shanghai, Rotterdam (The Netherlands), and Cambridge, Mass. Harbour BioMed discovers and develops innovative therapeutics for cancer with a focus on immuno-oncology and immunological diseases. Its discovery platforms center on two patented transgenic "Harbour Mice" strains (H2L2 and HCAb) owned by Harbour Antibodies BV for human antibody discovery. The company builds a proprietary pipeline through internal discovery programs, in-licensing clinical-stage assets, and licensing its platforms to partners and academic institutions. Within its first year it acquired and integrated Harbour Antibodies BV and has since licensed in two clinical-stage biologics and assembled an experienced clinical development and regulatory science team. Management plans to submit at least two INDs in 2018 targeting multiple indications for Chinese patients. Harbour BioMed is headquartered with R&D centers in China and maintains a Business Operation and Innovation Center in Boston and an Antibody Technology Innovation Center in Rotterdam.

Led · Equity · Nov 2016

Rokid is a human-computer interaction company that designs and manufactures augmented-reality hardware and software, most recently launching the 49-gram Rokid Glasses, billed as the world’s lightest full-function AI & AR smart glasses. The device runs on the Qualcomm AR1 platform and incorporates dual Micro LED waveguide displays, a 12-megapixel Sony IMX681 camera, and AI-driven features such as real-time translation, object recognition, live transcription, navigation, teleprompter capabilities, and voice interaction. Its open SDK lets developers tap into services like ChatGPT, Gemini, Google Maps, Microsoft Translator, and custom large language models, positioning the product as an extensible platform rather than a closed ecosystem. Rokid claims the largest XR developer community in China and has won three consecutive CES Innovation Awards and five German iF Design Awards. To build momentum, the company undertook a “Future in Sight” world tour with live demos across the United States, Germany, Singapore, and France, and launched a “Go Global with Rokid Glasses” creator program that funded user-generated travel stories captured through the glasses. The recent Kickstarter campaign drew over 5,000 backers and raised $3.6 million, providing the firm with capital for global rollout and validating consumer demand for intelligent, lightweight smart eyewear.